Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer.
Hernando-Calvo A, Han M, Ayodele O, Wang BX, Bruce JP, Abbas-Aghababazadeh F, Vila-Casadesús M, Sanz-Garcia E, Yang SYC, Berman HK, Vivancos A, Lam B, Lungu I, Salawu A, Stayner LA, Haibe-Kains B, Bedard PL, Avery L, Razak ARA, Pugh TJ, Spreafico A, Siu LL, Hansen AR. Hernando-Calvo A, et al. Among authors: wang bx. Clin Colorectal Cancer. 2024 Sep;23(3):272-284.e9. doi: 10.1016/j.clcc.2024.05.002. Epub 2024 May 15. Clin Colorectal Cancer. 2024. PMID: 38960798 Free article. Clinical Trial.
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Salawu A, Wang BX, Han M, Geady C, Heirali A, Berman HK, Pfister TD, Hernando-Calvo A, Al-Ezzi EM, Stayner LA, Gupta AA, Ayodele O, Lam B, Hansen AR, Spreafico A, Bedard PL, Butler MO, Avery L, Coburn B, Haibe-Kains B, Siu LL, Abdul Razak AR. Salawu A, et al. Among authors: wang bx. Clin Cancer Res. 2023 Oct 13;29(20):4128-4138. doi: 10.1158/1078-0432.CCR-23-1137. Clin Cancer Res. 2023. PMID: 37566240
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors.
Taylor K, Loo Yau H, Chakravarthy A, Wang B, Shen SY, Ettayebi I, Ishak CA, Bedard PL, Abdul Razak A, R Hansen A, Spreafico A, Cescon D, Butler MO, Oza AM, Lheureux S, Stjepanovic N, Van As B, Boross-Harmer S, Wang L, Pugh TJ, Ohashi PS, Siu LL, De Carvalho DD. Taylor K, et al. J Immunother Cancer. 2020 Aug;8(2):e000883. doi: 10.1136/jitc-2020-000883. J Immunother Cancer. 2020. PMID: 32753546 Free PMC article. Clinical Trial.
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity.
Cindy Yang SY, Lien SC, Wang BX, Clouthier DL, Hanna Y, Cirlan I, Zhu K, Bruce JP, El Ghamrasni S, Iafolla MAJ, Oliva M, Hansen AR, Spreafico A, Bedard PL, Lheureux S, Razak A, Speers V, Berman HK, Aleshin A, Haibe-Kains B, Brooks DG, McGaha TL, Butler MO, Bratman SV, Ohashi PS, Siu LL, Pugh TJ. Cindy Yang SY, et al. Among authors: wang bx. Nat Commun. 2021 Aug 26;12(1):5137. doi: 10.1038/s41467-021-25432-7. Nat Commun. 2021. PMID: 34446728 Free PMC article. Clinical Trial.
Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab.
Watson GA, Sanz-Garcia E, Zhang WJ, Liu ZA, Yang SC, Wang B, Liu S, Kubli S, Berman H, Pfister T, Genta S, Spreafico A, Hansen AR, Bedard PL, Lheureux S, Abdul Razak A, Cescon D, Butler MO, Xu W, Mak TW, Siu LL, Chen E. Watson GA, et al. J Immunother Cancer. 2022 Jun;10(6):e004378. doi: 10.1136/jitc-2021-004378. J Immunother Cancer. 2022. PMID: 35705312 Free PMC article.
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study.
Oliva M, Chepeha D, Araujo DV, Diaz-Mejia JJ, Olson P, Prawira A, Spreafico A, Bratman SV, Shek T, de Almeida J, R Hansen A, Hope A, Goldstein D, Weinreb I, Smith S, Perez-Ordoñez B, Irish J, Torti D, Bruce JP, Wang BX, Fortuna A, Pugh TJ, Der-Torossian H, Shazer R, Attanasio N, Au Q, Tin A, Feeney J, Sethi H, Aleshin A, Chen I, Siu L. Oliva M, et al. Among authors: wang bx. J Immunother Cancer. 2021 Oct;9(10):e003476. doi: 10.1136/jitc-2021-003476. J Immunother Cancer. 2021. PMID: 34599023 Free PMC article.
All is not lost: learning from 9p21 loss in cancer.
Spiliopoulou P, Yang SYC, Bruce JP, Wang BX, Berman HK, Pugh TJ, Siu LL. Spiliopoulou P, et al. Among authors: wang bx. Trends Immunol. 2022 May;43(5):379-390. doi: 10.1016/j.it.2022.03.003. Epub 2022 Apr 1. Trends Immunol. 2022. PMID: 35379580 Free article. Review.
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy.
Boukhaled GM, Gadalla R, Elsaesser HJ, Abd-Rabbo D, Quevedo R, Yang SYC, Guo M, Wang BX, Noamani B, Gray D, Lau SCM, Taylor K, Aung K, Spreafico A, Hansen AR, Saibil SD, Hirano N, Guidos C, Pugh TJ, McGaha TL, Ohashi PS, Sacher AG, Butler MO, Brooks DG. Boukhaled GM, et al. Among authors: wang bx. Nat Immunol. 2022 Aug;23(8):1273-1283. doi: 10.1038/s41590-022-01262-7. Epub 2022 Jul 14. Nat Immunol. 2022. PMID: 35835962
378 results